Clinical data | |
---|---|
Other names | SHR3680 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H20F3N3O4S |
Molar mass | 479.47 g·mol−1 |
3D model (JSmol) | |
| |
|
Rezvilutamide (INN ),[1][2] sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer.[3][4][5] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][5] The drug was developed by Jiangsu Hengrui Medicine.[3] Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.